文献速递妇科

GOG 9923事后分析:BRCA状态是否影响毒性?

Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
PubMed 文献 · Gynecol Oncol · 2021-02-17

结果显示BRCA相关肿瘤与野生型肿瘤在贫血、发热性中性粒细胞减少、腹痛、结肠穿孔、恶心、呕吐及外周感觉神经病变发生率上相似,中位无进展生存期无显著差异(HR 0.96,CI 0.65-1.42)。

要点

  • BRCA相关与野生型卵巢癌患者化疗毒性发生率相似。
  • 中位PFS两组无显著差异(HR 0.96,CI 0.65-1.42)。
  • 研究主要目的非评估结局,结论需谨慎解读。

核心结论

  • 在新诊断上皮性卵巢癌患者中,BRCA相关肿瘤与野生型肿瘤之间未观察到报告毒性的差异。

主要发现

  • BRCA相关与野生型肿瘤患者贫血、发热性中性粒细胞减少、腹痛、结肠穿孔、恶心、呕吐及外周感觉神经病变发生率相似。
  • 中位无进展生存期在BRCA相关与野生型肿瘤间无显著差异(HR 0.96,CI 0.65-1.42)。

临床怎么用

  • 对于新诊断上皮性卵巢癌患者,BRCA状态可能不影响含veliparib和贝伐珠单抗化疗方案的毒性管理。

局限性

  • 本研究为未计划的事后分析,主要目的非评估结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate how women with epithelial ovarian cancer (EOC), dichotomized by BRCA status, tolerate intravenous (IV) or intraperitoneal (IP) chemotherapy given with veliparib and bevacizumab (bev) on a GOG phase I study (GOG 9923, NCT00989651). METHODS: This is an unplanned, post hoc analysis of an IRB approved, multi-institutional, prospective study (GOG 9923). Clinical characteristics and toxicity data based on BRCA status were evaluated and descriptive statistics were used to summarize baseline patient characteristics and toxicities. The Kaplan Meier method was used to generate survival estimates. RESULTS: Four hundred twenty-four patients were evaluable. Patients were treated with IV carboplatin, paclitaxel, and bev every 21 days (regimen 1), weekly IV paclitaxel with carboplatin and bev (regimen 2) or IV paclitaxel and bev with IP cisplatin (regimen 3). Bev was continued as maintenance in all arms. Within each of these regimens, veliparib was given either twice daily for the entirety of each cycle (continuous) or on days -2 to 5 (intermittent). Ten percent of patients treated on regimen 1, 12% on regimen 2, and 19.8% on regimen 3 had BRCA-associated tumors. Patients with BRCA-associated tumors, when compared to wild type, experienced similar rates of anemia, febrile neutropenia (, abdominal pain, colonic perforation, nausea, vomiting, and peripheral sensory neuropathy. Median progression free survival (PFS) was not significantly different between BRCA-associated and wild type cancers (HR 0.96, CI 0.65-1.42), though this study's primary aim was not to evaluate outcomes. CONCLUSIONS: Germline BRCA mutations positively affect chemosensitivity in EOC, but whether differences in toxicities among BRCA-associated and BRCA wild type tumors existed was previously not reported. In this population with newly diagnosed ovarian cancer no differences in reported toxicity between the two groups was observed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gillen J, Miller A, Bell-McGuinn KM, et al. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021. PMID: 33610319. doi:10.1016/j.ygyno.2021.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。